



PRESS RELEASE March 29, 2007

The Board of Directors' Dividend Proposal to the Annual General Meeting of Biovitrum

The Board of Directors in Biovitrum AB (publ) has decided to propose the Annual General Meeting on May 3rd, that no dividend should be made for the financial year 2006.

For additional information, please contact:

Biovitrum AB (publ)

Anders Martin-Löf, Director Investor Relations
Phone: +46 8 697 37 07, cell phone: +46 70 624 32 56
anders.martin-lof@biovitrum.com

Anna Karin Källén, Vice President, Corporate Communications
Phone: +46 8 697 20 85, cell phone: +46 73 433 20 85
annakarin.kallen@biovitrum.com

About Biovitrum

Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum has a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for the treatment of obesity, diabetes, inflammation and eye and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has revenues of approximately SEK 1.2 billion and 550 employees. Biovitrum is listed on the Stockholm Stock Exchange since September 15, 2006. For more information see www.biovitrum.com.